GLP-1 Misinformation Forces Clinicians to Correct
Clinicians say they correct false GLP-1 weight loss claims weekly, and counterfeit sellers are facing new scrutiny.
Updated on Nov. 3, 2026 in Weight Loss
Live Poll
Do you trust health information you see on social media?
Clinicians report that misinformation about GLP-1 weight loss drugs requires frequent correction, with 73 per cent of clinicians correcting it at least once a week. Novo Nordisk has also applied for a website-blocking order against six UK internet service providers targeting counterfeit GLP-1 sellers.
Why it matters
For people considering GLP-1 weight loss medications, misleading information from social media and unlicensed sellers can shape decisions about safety and care. Counterfeit suppliers and telehealth companies with misleading advertising are cited as contributors to the problem, which regulators and the manufacturer are now pursuing directly.
The figures come from a survey of clinicians asked where their patients' GLP-1 misinformation originates, and they show that correcting false claims is a routine part of the job. The survey does not report its sample size or methodology in the material available here, so the percentages should be read as clinician perceptions rather than measured exposure.
The players
Novo Nordisk
A Danish pharmaceutical company best known for its GLP-1 diabetes and obesity treatments, including semaglutide-based therapies.
U.S. Food and Drug Administration
The U.S. federal agency that regulates prescription drugs and issues warnings over misleading drug advertising.
The details
GLP-1 drugs mimic a gut hormone that helps regulate appetite and blood sugar, and they are prescribed for weight management and diabetes. Misinformation spreads through short-form video and social platforms, where influencers may exaggerate benefits and leave out alternatives, according to earlier research. Counterfeit suppliers and telehealth companies with misleading ads add to the confusion, which is why the FDA has issued thousands of warning letters over a six-month period.
Timeline
Over a six-month period, the FDA issued thousands of warning letters to telehealth companies over misleading GLP-1 ads.
Earlier this year, researchers found health influencers exaggerate benefits and omit alternatives.
Recently, Novo Nordisk applied for a UK website-blocking order against counterfeit sellers.
Health Landscape
GLP-1 drugs have become central to weight management care, and their rapid uptake has been accompanied by a surge in counterfeit products and promotional content that outpaces clinical guidance. Regulatory action against telehealth advertising and counterfeit sellers reflects an effort to bring online marketing in line with the evidence base for these treatments.
If you are considering a GLP-1 medication, it is worth raising questions about safety and sourcing with your clinician rather than relying on social media claims. Be cautious of products offered without a prescription or from unverified sellers, and discuss any concerns about what you have been told with your doctor.
The takeaway
Misinformation about GLP-1 drugs is common enough that clinicians correct it weekly, so checking claims against your prescriber is a useful habit. Treat unlicensed sellers and influencer endorsements with skepticism, and bring any questions to a licensed healthcare professional.
Further reading
For more on the treatments at the center of this debate, explore our Weight Loss coverage.
Source note: This article includes information reported by Forbes.
Live Poll
Do you trust health information you see on social media?
